The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives

Experimental Hematology & Oncology

Review

Giuseppe D’Aquino¹  Antonia Mancuso¹  Pierosandro Tagliaferri¹  Caterina Riillo¹  Daniele Caracciolo¹  Nicoletta Poler๠ Caterina Froio¹  Pierfrancesco Tassone² 

[1] Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy;Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy;Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA;

关键词: T-ALL;    Acute Lymphoblastic Leukemia;    CAR-T;    Bispecific T-cell engagers;    BTCEs;    Immunotherapy;    Hematological malignancies;   

DOI  :  10.1186/s40164-022-00368-w

 received in 2022-10-29, accepted in 2022-12-30,  发布年份 2022

来源: Springer

【 摘 要 】

T-cell acute lymphoblastic leukemia (T-ALL) is a challenging pediatric and adult haematologic disease still associated with an unsatisfactory cure rate. Unlike B-ALL, the availability of novel therapeutic options to definitively improve the life expectancy for relapsed/resistant patients is poor. Indeed, the shared expression of surface targets among normal and neoplastic T-cells still limits the efficacy and may induce fratricide effects, hampering the use of innovative immunotherapeutic strategies. However, novel monoclonal antibodies, bispecific T-cell engagers (BTCEs), and chimeric antigen receptors (CAR) T-cells recently showed encouraging results and some of them are in an advanced stage of pre-clinical development or are currently under investigation in clinical trials. Here, we review this exciting scenario focusing on most relevant advances, challenges, and perspectives of the emerging landscape of immunotherapy of T-cell malignancies.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 4

Fig. 59

Fig. 5